Zydus Lifesciences Ltd s subsidiary Zydus Pharmaceuticals USA Inc. has received tentative approval from the USFDA to market Levomilnacipran Extended-Release Capsules, 20 mg, 40 mg, 80 mg, and 120 mg
Potassium Chloride Oral Solution is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium rich foods or.